Literature DB >> 25899669

Phenotypic variation of TTC19-deficient mitochondrial complex III deficiency: a case report and literature review.

Dylan A Mordaunt1,2, Alexandra Jolley1, Shanti Balasubramaniam1,3,4, David R Thorburn5,6, Hayley S Mountford5,6, Alison G Compton5,6, Jillian Nicholl1, Nicholas Manton1, Damian Clark7, Drago Bratkovic1, Kathryn Friend1,2, Sui Yu1.   

Abstract

Isolated mitochondrial respiratory chain complex III deficiency has been described in a heterogeneous group of clinical presentations in children and adults. It has been associated with mutations in MT-CYB, the only mitochondrial DNA encoded subunit, as well as in nine nuclear genes described thus far: BCS1L, TTC19, UQCRB, UQCRQ, UQCRC2, CYC1, UQCC2, LYRM7, and UQCC3. BCS1L, TTC19, UQCC2, LYRM7, and UQCC3 are complex III assembly factors. We report on an 8-year-old girl born to consanguineous Iraqi parents presenting with slowly progressive encephalomyopathy, severe failure to thrive, significant delays in verbal and communicative skills and bilateral retinal cherry red spots on fundoscopy. SNP array identified multiple regions of homozygosity involving 7.5% of the genome. Mutations in the TTC19 gene are known to cause complex III deficiency and TTC19 was located within the regions of homozygosity. Sequencing of TTC19 revealed a homozygous nonsense mutation at exon 6 (c.937C > T; p.Q313X). We reviewed the phenotypes and genotypes of all 11 patients with TTC19 mutations leading to complex III deficiency (including our case). The consistent features noted are progressive neurodegeneration with Leigh-like brain MRI abnormalities. Significant variability was observed however with the age of symptom onset and rate of disease progression. The bilateral retinal cherry red spots and failure to thrive observed in our patient are unique features, which have not been described, in previously reported patients with TTC19 mutations. Interestingly, all reported TTC19 mutations are nonsense mutations. The severity of clinical manifestations however does not specifically correlate with the residual complex III enzyme activities.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  TTC19; cytochrome bc1 complex; mitochondrial complex III; mitochondrial encephalomyopathy; ubiquinol-cytochrome c oxidoreductase

Mesh:

Substances:

Year:  2015        PMID: 25899669     DOI: 10.1002/ajmg.a.36968

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Mitochondrial complex III Rieske Fe-S protein processing and assembly.

Authors:  Erika Fernandez-Vizarra; Massimo Zeviani
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

Review 2.  Mitochondrial Structure and Bioenergetics in Normal and Disease Conditions.

Authors:  Margherita Protasoni; Massimo Zeviani
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 5.923

3.  Exploiting pyocyanin to treat mitochondrial disease due to respiratory complex III dysfunction.

Authors:  Roberta Peruzzo; Samantha Corrà; Roberto Costa; Michele Brischigliaro; Tatiana Varanita; Lucia Biasutto; Chiara Rampazzo; Daniele Ghezzi; Luigi Leanza; Mario Zoratti; Massimo Zeviani; Cristiano De Pittà; Carlo Viscomi; Rodolfo Costa; Ildikò Szabò
Journal:  Nat Commun       Date:  2021-04-08       Impact factor: 17.694

4.  Camptocormia and Other Orthopedic Compromise Dominating Mitochondrial Disorder: A Case Report.

Authors:  Josef Finsterer; Subhankar Chatterjee; Ritwik Ghosh
Journal:  Cureus       Date:  2020-12-03

Review 5.  Organization of the Respiratory Supercomplexes in Cells with Defective Complex III: Structural Features and Metabolic Consequences.

Authors:  Michela Rugolo; Claudia Zanna; Anna Maria Ghelli
Journal:  Life (Basel)       Date:  2021-04-17

Review 6.  The genetics and pathology of mitochondrial disease.

Authors:  Charlotte L Alston; Mariana C Rocha; Nichola Z Lax; Doug M Turnbull; Robert W Taylor
Journal:  J Pathol       Date:  2016-11-02       Impact factor: 7.996

7.  Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.

Authors:  Yingyan Han; Peng Wu; Zhi Wang; Zeyu Zhang; Shujuan Sun; Jia Liu; Song Gong; Peipei Gao; Tomoo Iwakuma; Miguel Angel Molina-Vila; Benjamin Ping-Chi Chen; Yu Zhang; Teng Ji; Qingqing Mo; Pingbo Chen; Junbo Hu; Shixuan Wang; Jianfeng Zhou; Hua Lu; Qinglei Gao
Journal:  EBioMedicine       Date:  2019-01-20       Impact factor: 8.143

Review 8.  Blackout in the powerhouse: clinical phenotypes associated with defects in the assembly of OXPHOS complexes and the mitoribosome.

Authors:  Daniella H Hock; David R L Robinson; David A Stroud
Journal:  Biochem J       Date:  2020-11-13       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.